Exploring therapeutical targets and innovative treatments for ischemic stroke: a comprehensive review

Lidija Radenovic

Exploration of Neuroprotective Therapy ›› 2024, Vol. 4 ›› Issue (6) : 459 -484.

PDF (4377KB)
Exploration of Neuroprotective Therapy ›› 2024, Vol. 4 ›› Issue (6) :459 -484. DOI: 10.37349/ent.2024.00094
Review
research-article
Exploring therapeutical targets and innovative treatments for ischemic stroke: a comprehensive review
Author information +
History +
PDF (4377KB)

Abstract

This review focuses on the current advances in the field of therapeutic targets and treatments for stroke. Stroke is a major health problem worldwide, with significant impacts on morbidity and mortality, and a considerable burden on the medical and socio-economic systems. This review provides a comprehensive overview of the current state of knowledge on acute treatments and therapeutic targets. Current stroke treatments like recanalization therapies focus mainly on restoring blood flow to the brain, reducing cell death, and preventing further damage, but have limitations in terms of efficacy and long-term outcomes. Besides acute treatments (mobile stroke units, telerehabilitation) and acute therapeutic targets, the review focuses on longer-term therapeutic targets, such as neuroprotection and neuroregeneration. Neuroprotective strategies target the mechanisms underlying energy failure, cellular acidosis, mitochondrial dysfunction, endoplasmic reticulum stress, excitotoxicity, calcium channels dysregulation, oxidative stress, neuroinflammation, blood-brain barrier disruption, apoptosis, and ischemia-reperfusion injury. Neuroregenerative approaches include stem cell therapy, gene therapy, growth factors, and rehabilitation techniques that promote the rewiring of neuronal circuits in the brain. Non-pharmacological treatments like neurostimulation and bioengineering are also presented. Additionally, we highlight the challenges and future directions in translating these therapies into clinical practice. Overall, the treatment of ischemic stroke is a complex and multifaceted process that requires a combination of acute measures as well as longer-term strategies to promote brain repair and recovery. The treatment of ischemic stroke has made significant progress in recent years with the development of new treatments and ongoing research to improve outcomes for stroke patients. However, before these therapies can be successfully integrated into routine clinical practise, further research is needed to establish standardised protocols, overcome methodological limitations, and overcome clinical challenges. By further deepening our understanding of the pathophysiology of ischemic stroke and developing innovative treatments, we can improve outcomes and quality of life for stroke survivors.

Keywords

Ischemic stroke / cerebral ischemia / treatment / target / stem cell and gene therapy / neuroregeneration / neuroprotection / rehabilitation

Cite this article

Download citation ▾
Lidija Radenovic. Exploring therapeutical targets and innovative treatments for ischemic stroke: a comprehensive review. Exploration of Neuroprotective Therapy, 2024, 4 (6) : 459-484 DOI:10.37349/ent.2024.00094

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Katan M, Luft A. Global Burden of Stroke. Semin Neurol. 2018; 38: 208-11.

[2]

Zhao Y, Zhang X, Chen X, Wei Y. Neuronal injuries in cerebral infarction and ischemic stroke: From mechanisms to treatment (Review). Int J Mol Med. 2022; 49: 15.

[3]

Khoshnam SE, Winlow W, Farzaneh M, Farbood Y, Moghaddam HF. Pathogenic mechanisms following ischemic stroke. Neurol Sci. 2017; 38: 1167-86.

[4]

del Zoppo GJ, Hallenbeck JM. Advances in the Vascular Pathophysiology of Ischemic Stroke. Thromb Res. 2000; 98: 73-81.

[5]

Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023; 147: e93-621.

[6]

Chung D, Lee JS, Oh MS, Park JM, Chung JW, Bang OY, et al. Temporal trends of sex differences in acute reperfusion therapy and early outcomes of acute ischemic stroke in South Korea: 10-year analysis of the nationwide stroke registry. Int J Stroke. 2024; 19: 1028-37.

[7]

Saini V, Guada L, Yavagal DR. Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions. Neurology. 2021; 97: S6-16.

[8]

Phipps MS, Cronin CA. Management of acute ischemic stroke. BMJ. 2020; 368: l6983.

[9]

Yang Y, Guo D, Liu Y, Li Y. Advances in neuroprotective therapy for acute ischemic stroke. Explor Neuroprot Ther. 2024; 4: 55-71.

[10]

Humphrey S, Pike KE, Long B, Ma H, Bourke R, Byrne D, et al. What does cognitive screening reveal about early cognitive performance following endovascular clot retrieval and intravenous thrombolysis in acute ischaemic stroke? Brain Impair. 2024; 25: IB23066.

[11]

Zamanlu M, Farhoudi M, Eskandani M, Mahmoudi J, Barar J, Rafi M, et al. Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke. J Drug Target. 2018; 26: 95-109.

[12]

Frank D, Zlotnik A, Boyko M, Gruenbaum BF. The Development of Novel Drug Treatments for Stroke Patients: A Review. Int J Mol Sci. 2022; 23: 5796.

[13]

Yin J, Wang S, Wang J, Zhang Y, Fan C, Chao J, et al. An intelligent DNA nanodevice for precision thrombolysis. Nat Mater. 2024; 23: 854-62.

[14]

Peng TJ, Schwamm LH, Fonarow GC, Hassan AE, Hill M, Messé SR, et al. Contemporary Prestroke Dual Antiplatelet Use and Symptomatic Intracerebral Hemorrhage Risk After Thrombolysis. JAMA Neurol. 2024; 81: 722-31.

[15]

Almegren M. Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Saudi Patients With Atrial Fibrillation. Cureus. 2024; 16: e58886.

[16]

Lehto M, Luojus A, Halminen O, Haukka J, Putaala J, Linna M, et al.; FinACAF Study Group. Time-in-therapeutic-range defined warfarin and direct oral anticoagulants in atrial fibrillation: a Nationwide Cohort Study. Ann Med. 2024; 56: 2364825.

[17]

Zhang J, Liu J, Li D, Zhang C, Liu M. Calcium antagonists for acute ischemic stroke. Cochrane Database Syst Rev. 2019; 2: CD001928.

[18]

Hussein HR, Chang CY, Zheng Y, Yang CY, Li LH, Lee YT, et al. Immune-stealth VP28-conjugated heparin nanoparticles for enhanced and reversible anticoagulation. Nanotechnology. 2024; 35: 175102.

[19]

Mele F, Gendarini C, Pantoni L. The use of dual antiplatelet therapy for ischemic cerebrovascular events. Neurol Sci. 2023; 44: 37-43.

[20]

Radenovic L. In Vivo Experimental Models of Cerebral Ischemia: Analysis, Translational Potential and Clinical Relevance. Cardiol Res Cardiovasc Med. 2024; 9: 232.

[21]

Rodgers H, Price C. Stroke unit care, inpatient rehabilitation and early supported discharge. Clin Med (Lond). 2017; 17: 173-7.

[22]

Luengo-Fernandez R, Violato M, Candio P, Leal J. Economic burden of stroke across Europe: A population-based cost analysis. Eur Stroke J. 2020; 5: 17-25.

[23]

Deng G, Chu YH, Xiao J, Shang K, Zhou LQ, Qin C, et al. Risk Factors, Pathophysiologic Mechanisms, and Potential Treatment Strategies of Futile Recanalization after Endovascular Therapy in Acute Ischemic Stroke. Aging Dis. 2023; 14: 2096-112.

[24]

Larcipretti ALL, Gomes FC, Dagostin CS, Nager GB, Udoma-Udofa OC, Pontes JPM, et al. Is time really brain in stroke therapy?: A meta-analysis of mechanical thrombectomy up to 155 h post ictus. Acta Neurochir (Wien). 2024; 166: 195.

[25]

Navi BB, Audebert HJ, Alexandrov AW, Cadilhac DA, Grotta JC ; PRESTO (Prehospital Stroke Treatment Organization) Writing Group. Mobile Stroke Units: Evidence, Gaps, and Next Steps. Stroke. 2022; 53: 2103-13.

[26]

Zuil-Escobar JC, Martín-Urrialde JA, Mesa-Jiménez JA, Palomo-Carrión R, Martínez-Cepa CB. Telehealth in Informal Caregivers of Stroke Survivors: A Systematic Review. J Clin Med. 2024; 13: 1810.

[27]

H Buck B, Akhtar N, Alrohimi A, Khan K, Shuaib A. Stroke mimics: incidence, aetiology, clinical features and treatment. Ann Med. 2021; 53: 420-36.

[28]

Campbell BC, Parsons MW. Imaging selection for acute stroke intervention. Int J Stroke. 2018; 13: 554-67.

[29]

Zeng H, Zhu Q. Application of imaging modalities for endovascular thrombectomy of large core infarcts in clinical practice. Front Neurol. 2024; 15: 1272890.

[30]

Abdalkader M, Siegler JE, Lee JS, Yaghi S, Qiu Z, Huo X, et al. Neuroimaging of Acute Ischemic Stroke: Multimodal Imaging Approach for Acute Endovascular Therapy. J Stroke. 2023; 25: 55-71.

[31]

Zhao Z, Zhang Y, Su J, Yang L, Pang L, Gao Y, et al. A comprehensive review for artificial intelligence on neuroimaging in rehabilitation of ischemic stroke. Front Neurol. 2024; 15: 1367854.

[32]

Smith LGF, Milliron E, Ho ML, Hu HH, Rusin J, Leonard J, et al. Advanced neuroimaging in traumatic brain injury: an overview. Neurosurg Focus. 2019; 47: E17.

[33]

Barca C, Wiesmann M, Calahorra J, Wachsmuth L, Döring C, Foray C, et al. Impact of hydroxytyrosol on stroke: tracking therapy response on neuroinflammation and cerebrovascular parameters using PET-MR imaging and on functional outcomes. Theranostics. 2021; 11: 4030-49.

[34]

Quintana DD, Garcia JA, Sarkar SN, Jun S, Engler-Chiurazzi EB, Russell AE, et al. Hypoxia-reoxygenation of primary astrocytes results in a redistribution of mitochondrial size and mitophagy. Mitochondrion. 2019; 47: 244-55.

[35]

Dhapola R, Medhi B, HariKrishnaReddy D. Insight into the pathophysiological advances and molecular mechanisms underlying cerebral stroke: current status. Mol Biol Rep. 2024; 51: 649.

[36]

Montiel T, Gómora-García JC, Gerónimo-Olvera C, Heras-Romero Y, Bernal-Vicente BN, Pérez-Martínez X, et al. Modulation of the autophagy-lysosomal pathway and endoplasmic reticulum stress by ketone bodies in experimental models of stroke. J Neurochem. 2023; 166: 87-106.

[37]

Ehresman J, Cottrill E, Caplan JM, McDougall CG, Theodore N, Nyquist PA. Neuroprotective Role of Acidosis in Ischemia: Review of the Preclinical Evidence. Mol Neurobiol. 2021; 58: 6684-96.

[38]

Rama R, García JC. Excitotoxicity and Oxidative Stress in Acute Stroke. In: Schaller B, editor. Ischemic Stroke-Updates. Rijeka: InTech; 2016. pp. 17-33.

[39]

Besancon E, Guo S, Lok J, Tymianski M, Lo EH. Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke. Trends Pharmacol Sci. 2008; 29: 268-75.

[40]

Sun Y, Feng X, Ding Y, Li M, Yao J, Wang L, et al. Phased Treatment Strategies for Cerebral Ischemia Based on Glutamate Receptors. Front Cell Neurosci. 2019; 13: 168.

[41]

Da Silva-Candal A, Maria-Perez-Mato, Castillo J. Treatments Against Glutamatergic Excitotoxicity in Ischemic Stroke. In: Pavlovic ZM, editor. Glutamate and Neuropsychiatric Disorders. Cham: Springer; 2022. pp. 1-25.

[42]

Rahi V, Kaundal RK. Exploring the intricacies of calcium dysregulation in ischemic stroke: Insights into neuronal cell death and therapeutic strategies. Life Sci. 2024; 347: 122651.

[43]

Lou G, Palikaras K, Lautrup S, Scheibye-Knudsen M, Tavernarakis N, Fang EF. Mitophagy and Neuroprotection. Trends Mol Med. 2020; 26: 8-20.

[44]

She R, Liu D, Liao J, Wang G, Ge J, Mei Z. Mitochondrial dysfunctions induce PANoptosis and ferroptosis in cerebral ischemia/reperfusion injury: from pathology to therapeutic potential. Front Cell Neurosci. 2023; 17: 1191629.

[45]

Shen L, Gan Q, Yang Y, Reis C, Zhang Z, Xu S, et al. Mitophagy in Cerebral Ischemia and Ischemia/Reperfusion Injury. Front Aging Neurosci. 2021; 13: 687246.

[46]

Zhang G, Wang Q, Jiang B, Yao L, Wu W, Zhang X, et al. Progress of medicinal plants and their active metabolites in ischemia-reperfusion injury of stroke: a novel therapeutic strategy based on regulation of crosstalk between mitophagy and ferroptosis. Front Pharmacol. 2024; 15: 1374445.

[47]

Carinci M, Vezzani B, Patergnani S, Ludewig P, Lessmann K, Magnus T, et al. Different Roles of Mitochondria in Cell Death and Inflammation: Focusing on Mitochondrial Quality Control in Ischemic Stroke and Reperfusion. Biomedicines. 2021; 9: 169.

[48]

Radenovic L, Korenic A, Maleeva G, Osadchenko I, Kovalenko T, Skibo G. Comparative Ultrastructural Analysis of Mitochondria in the CA1 and CA3 Hippocampal Pyramidal Cells Following Global Ischemia in Mongolian Gerbils. Anat Rec (Hoboken). 2011; 294: 1057-65.

[49]

Xian H, Liou YC. Functions of outer mitochondrial membrane proteins: mediating the crosstalk between mitochondrial dynamics and mitophagy. Cell Death Differ. 2021; 28: 827-42.

[50]

Mo Y, Sun YY, Liu KY. Autophagy and inflammation in ischemic stroke. Neural Regen Res. 2020; 15: 1388-96.

[51]

Ajoolabady A, Wang S, Kroemer G, Penninger JM, Uversky VN, Pratico D, et al. Targeting Autophagy in Ischemic Stroke: From Molecular Mechanisms to Clinical Therapeutics. Pharmacol Ther. 2021; 225: 107848.

[52]

Yu X, Dang L, Zhang R, Yang W. Therapeutic Potential of Targeting the PERK Signaling Pathway in Ischemic Stroke. Pharmaceuticals (Basel). 2024; 17: 353.

[53]

Manzoor S, Almarghalani DA, James AW, Raza MK, Kausar T, Nayeem SM, et al. Synthesis and Pharmacological Evaluation of Novel Triazole-Pyrimidine Hybrids as Potential Neuroprotective and Anti-neuroinflammatory Agents. Pharm Res. 2023; 40: 167-85.

[54]

Liu C, Chen H, Tao X, Li C, Li A, Wu W. ALKBH5 protects against stroke by reducing endoplasmic reticulum stress-dependent inflammation injury via the STAT5/PERK/EIF2α/CHOP signaling pathway in an m6A-YTHDF1-dependent manner. Exp Neurol. 2024; 372: 114629.

[55]

Wang L, Liu Y, Zhang X, Ye Y, Xiong X, Zhang S, et al. Endoplasmic Reticulum Stress and the Unfolded Protein Response in Cerebral Ischemia/Reperfusion Injury. Front Cell Neurosci. 2022; 16: 864426.

[56]

Zhang YP, Yang Q, Li YA, Yu MH, He GW, Zhu YX, et al. Inhibition of the Activating Transcription Factor 6 Branch of Endoplasmic Reticulum Stress Ameliorates Brain Injury after Deep Hypothermic Circulatory Arrest. J Clin Med. 2023; 12: 814.

[57]

Chen Z, Wang X, Wu H, Fan Y, Yan Z, Lu C, et al. X-box binding protein 1 as a key modulator in “healing endothelial cells”, a novel EC phenotype promoting angiogenesis after MCAO. Cell Mol Biol Lett. 2022; 27: 97.

[58]

Radenović L, Selaković V. Glutamate Neurotoxicity, Oxidative Stress and Mechanisms of Protection in the Rat Brain. In: Chen FJ, editor. Trends in Brain Mapping Research. New York: Nova Science Publishers; 2007. pp. 253-71.

[59]

Di Napoli M, Shah IM. Neuroinflammation and Cerebrovascular Disease in Old Age: A Translational Medicine Perspective. J Aging Res. 2016; 2016: 857484.

[60]

Rodrigo R, Fernández-Gajardo R, Gutiérrez R, Matamala JM, Carrasco R, Miranda-Merchak A, et al. Oxidative Stress and Pathophysiology of Ischemic Stroke: Novel Therapeutic Opportunities. CNS Neurol Disord Drug Targets. 2013; 12: 698-714.

[61]

Komakula S, Bhatia R, Sahib A, Upadhyay A, S LJ, Garg A, et al. Safety and efficacy of N-acetylcysteine (NAC) as an adjunct to standard treatment in patients with acute ischemic stroke: a randomized controlled pilot trial (NACTLYS) . Sci Rep. 2024; 14: 1103.

[62]

Wang TS, Jing LJ. Therapeutic effect and psychological impact of aspirin plus edaravone on patients with cerebral infarction. World J Psychiatry. 2024; 14: 644-52.

[63]

Kim ES, Shin Y, Kim EH, Kim D, De Felice M, Majid A, et al. Neuroprotective efficacy of N-t-butylhydroxylamine (NtBHA) in transient focal ischemia in rats. Toxicol Res. 2022; 38: 479-86.

[64]

Zhu G, Wang X, Chen L, Lenahan C, Fu Z, Fang Y, et al. Crosstalk Between the Oxidative Stress and Glia Cells After Stroke: From Mechanism to Therapies. Front Immunol. 2022; 13: 852416.

[65]

Iadecola C. The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease. Neuron. 2017; 96: 17-42.

[66]

Bayir E, Sendemir A. Role of Intermediate Filaments in Blood-Brain Barrier in Health and Disease. Cells. 2021; 10: 1400.

[67]

Li Y, Zhong W, Jiang Z, Tang X. New progress in the approaches for blood-brain barrier protection in acute ischemic stroke. Brain Res Bull. 2019; 144: 46-57.

[68]

Nian K, Harding IC, Herman IM, Ebong EE. Blood-Brain Barrier Damage in Ischemic Stroke and Its Regulation by Endothelial Mechanotransduction. Front Physiol. 2020; 11: 605398.

[69]

Spitzer D, Guérit S, Puetz T, Khel MI, Armbrust M, Dunst M, et al. Profiling the neurovascular unit unveils detrimental effects of osteopontin on the blood-brain barrier in acute ischemic stroke. Acta Neuropathol. 2022; 144: 305-37.

[70]

Chaturvedi M, Kaczmarek L. Mmp-9 Inhibition: a Therapeutic Strategy in Ischemic Stroke. Mol Neurobiol. 2014; 49: 563-73.

[71]

Hong JM, Kim DS, Kim M. Hemorrhagic Transformation After Ischemic Stroke: Mechanisms and Management. Front Neurol. 2021; 12: 703258.

[72]

Zhang L, Zhang ZG, Chopp M. The neurovascular unit and combination treatment strategies for stroke. Trends Pharmacol Sci. 2012; 33: 415-22.

[73]

Lyden PD. Cerebroprotection for Acute Ischemic Stroke: Looking Ahead. Stroke. 2021; 52: 3033-44.

[74]

Ji Y, Gao Q, Ma Y, Wang F, Tan X, Song D, et al. An MMP-9 exclusive neutralizing antibody attenuates blood-brain barrier breakdown in mice with stroke and reduces stroke patient-derived MMP-9 activity. Pharmacol Res. 2023; 190: 106720.

[75]

Pluta R, Januszewski S, Czuczwar SJ. Neuroinflammation in Post-Ischemic Neurodegeneration of the Brain: Friend, Foe, or Both? Int J Mol Sci. 2021; 22: 4405.

[76]

Dugue R, Nath M, Dugue A, Barone FC. Roles of Pro- and Anti-inflammatory Cytokines in Traumatic Brain Injury and Acute Ischemic Stroke. In: Abreu GEA, editor. Mechanisms of Neuroinflammation. Rijeka: InTech; 2017.

[77]

Živančević K, Lović D, Andjus PR, Radenović L, Pluta R. Neuroinflammation in Post-Ischemic Brain. In: Pluta R, editor. Cerebral Ischemia. Brisbane (AU): Exon Publications; 2021.

[78]

Sekeljic V, Bataveljic D, Stamenkovic S, Ułamek M, Jabłoński M, Radenovic L, et al. Cellular markers of neuroinflammation and neurogenesis after ischemic brain injury in the long-term survival rat model. Brain Struct Funct. 2012; 217: 411-20.

[79]

Radenovic L, Nenadic M, Ułamek-Kozioł M, Januszewski S, Czuczwar SJ, Andjus PR, et al. Heterogeneity in brain distribution of activated microglia and astrocytes in a rat ischemic model of Alzheimer’s disease after 2 years of survival. Aging (Albany NY). 2020; 12: 12251-67.

[80]

Cao Y, Yue X, Jia M, Wang J. Neuroinflammation and anti-inflammatory therapy for ischemic stroke. Heliyon. 2023; 9:e17986.

[81]

Wang H, Han S, Xie J, Zhao R, Li S, Li J. IL-17A exacerbates caspase-12-dependent neuronal apoptosis following ischemia through the Src-PLCγ-calpain pathway. Exp Neurol. 2024; 379: 114863.

[82]

Zhang K, Wang ZC, Sun H, Long H, Wang Y. Esculentoside H reduces the PANoptosis and protects the blood-brain barrier after cerebral ischemia/reperfusion through the TLE1/PI3K/AKT signaling pathway. Exp Neurol. 2024; 379: 114850.

[83]

Kang JB, Koh PO. Retinoic acid alleviates the reduction of Akt and Bad phosphorylation and regulates Bcl-2 family protein interactions in animal models of ischemic stroke. PLoS One. 2024; 19: e0303213.

[84]

Denorme F, Portier I, Rustad JL, Cody MJ, de Araujo CV, Hoki C, et al. Neutrophil extracellular traps regulate ischemic stroke brain injury. J Clin Invest. 2022; 132: e154225.

[85]

Denorme F, Ajanel A, Campbell RA. Immunothrombosis in neurovascular disease. Res Pract Thromb Haemost. 2023; 8: 102298.

[86]

von Brühl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012; 209: 819-35.

[87]

Jurcau A, Ardelean IA. Molecular pathophysiological mechanisms of ischemia/reperfusion injuries after recanalization therapy for acute ischemic stroke. J Integr Neurosci. 2021; 20: 727-44.

[88]

Hong JM, Lee JS, Song HJ, Jeong HS, Choi HA, Lee K. Therapeutic Hypothermia After Recanalization in Patients With Acute Ischemic Stroke. Stroke. 2014; 45: 134-40.

[89]

Kim JY, Kim JH, Park J, Beom JH, Chung SP, You JS, et al. Targeted Temperature Management at 36°C Shows Therapeutic Effectiveness via Alteration of Microglial Activation and Polarization After Ischemic Stroke. Transl Stroke Res. 2022; 13: 132-41.

[90]

Yao H, Zhao J, Song X. Protective effects of fraxin on cerebral ischemia-reperfusion injury by mediating neuroinflammation and oxidative stress through PPAR-γ/NF-κB pathway. Brain Res Bull. 2022; 187: 49-62.

[91]

Hougaard KD, Hjort N, Zeidler D, Sørensen L, Nørgaard A, Hansen TM, et al. Remote Ischemic Perconditioning as an Adjunct Therapy to Thrombolysis in Patients With Acute Ischemic Stroke: A Randomized Trial. Stroke. 2014; 45: 159-67.

[92]

D’Apolito E, Sisalli MJ, Tufano M, Annunziato L, Scorziello A. Oxidative Metabolism in Brain Ischemia and Preconditioning: Two Sides of the Same Coin. Antioxidants (Basel). 2024; 13: 547.

[93]

Zhao T, Li M, Yan Q, Gu J, Liu L. Effect of remote ischemic preconditioning intervention on serum levels of microRNA-582-5p/HMGB1 in patients with acute cerebral infarction. Clin Neurol Neurosurg. 2024; 241: 108291.

[94]

Zhang L, Yang M, Wang Z, Fan D, Shen F, Zou X, et al. Sevoflurane postconditioning ameliorates cerebral hypoxia/reoxygenation injury in zebrafish involving the Akt/GSK-3β pathway activation and the microtubule-associated protein 2 promotion. Biomed Pharmacother. 2024; 175: 116693.

[95]

Stamenkovic S, Sekeljic V, Radenovic L, Andjus RP. Ischemia and Neurogenesis: Link between Neurodegeneration and Repair. In: Clark GJ, Anderson WT, editors. Neurogenesis Research: New Developments. New York: Nova Science Publishers; 2012. pp. 115-36.

[96]

Radenovic L, Andjus P. Stroke and Alzheimer’s Disease: Common Mechanisms and Therapeutic Approaches. In: Pluta R, editor. Brain Ischemia: Alzheimer’s Disease Mechanisms. New York: Nova Science Publishers; 2019. pp. 251-64.

[97]

Paul S, Candelario-Jalil E. Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies. Exp Neurol. 2021; 335: 113518.

[98]

Fruhwirth V, Berger L, Gattringer T, Fandler-Höfler S, Kneihsl M, Eppinger S, et al. White matter integrity and functional connectivity of the default mode network in acute stroke are associated with cognitive outcome three months post-stroke. J Neurol Sci. 2024; 462: 123071.

[99]

Li Y, Schappell LE, Polizu C, DiPersio J, Tsirka SE, Halterman MW, et al. Evolving Clinical-Translational Investigations of Cerebroprotection in Ischemic Stroke. J Clin Med. 2023; 12: 6715.

[100]

Wang SN, Wang Z, Wang XY, Zhang XP, Xu TY, Miao CY. Humanized cerebral organoids-based ischemic stroke model for discovering of potential anti-stroke agents. Acta Pharmacol Sin. 2023; 44: 513-23.

[101]

Yasuhara T, Kawauchi S, Kin K, Morimoto J, Kameda M, Sasaki T, et al. Cell therapy for central nervous system disorders: Current obstacles to progress. CNS Neurosci Ther. 2020; 26: 595-602.

[102]

Hachimi-Idrissi S. Stem cell therapy in neurological disorders: promises and concerns. Explor Neuroprot Ther. 2023; 3: 346-62.

[103]

Mitrečić D, Hribljan V, Jagečić D, Isaković J, Lamberto F, Horánszky A, et al. Regenerative Neurology and Regenerative Cardiology: Shared Hurdles and Achievements. Int J Mol Sci. 2022; 23: 855.

[104]

Liu X, Jia X. Neuroprotection of Stem Cells Against Ischemic Brain Injury: From Bench to Clinic. Transl Stroke Res. 2024; 15: 691-713.

[105]

He J, Liu J, Huang Y, Tang X, Xiao H, Hu Z. Oxidative Stress, Inflammation, and Autophagy: Potential Targets of Mesenchymal Stem Cells-Based Therapies in Ischemic Stroke. Front Neurosci. 2021; 15: 641157.

[106]

Baker EW, Kinder HA, West FD. Neural stem cell therapy for stroke: A multimechanistic approach to restoring neurological function. Brain Behav. 2019; 9: e01214.

[107]

Han M, Zhang Z, Liu Z, Liu Y, Zhao H, Wang B, et al. Three-dimensional-cultured MSC-derived exosome with hydrogel for cerebral ischemia repair. Biomater Adv. 2023; 149: 213396.

[108]

Tuazon JP, Castelli V, Borlongan CV. Drug-like delivery methods of stem cells as biologics for stroke. Expert Opin Drug Deliv. 2019; 16: 823-33.

[109]

Aleynik A, Gernavage KM, Mourad YS, Sherman LS, Liu K, Gubenko YA, et al. Stem cell delivery of therapies for brain disorders. Clin Transl Med. 2014; 3: 24.

[110]

Sanberg PR, Eve DJ, Metcalf C, Borlongan CV. Advantages and challenges of alternative sources of adult-derived stem cells for brain repair in stroke. Prog Brain Res. 2012; 201: 99-117.

[111]

Ge L, Yang FH, Li W, Wang T, Lin Y, Feng J, et al. In vivo Neuroregeneration to Treat Ischemic Stroke Through NeuroD1 AAV-Based Gene Therapy in Adult Non-human Primates. Front Cell Dev Biol. 2020; 8: 590008.

[112]

Salikhova D, Bukharova T, Cherkashova E, Namestnikova D, Leonov G, Nikitina M, et al. Therapeutic Effects of hiPSC-Derived Glial and Neuronal Progenitor Cells-Conditioned Medium in Experimental Ischemic Stroke in Rats. Int J Mol Sci. 2021; 22: 4694.

[113]

Rajamanickam G, Lee ATH, Liao P. Role of Brain Derived Neurotrophic Factor and Related Therapeutic Strategies in Central Post-Stroke Pain. Neurochem Res. 2024; 49: 2303-18.

[114]

Keuters MH, Antila S, Immonen R, Plotnikova L, Wojciechowski S, Lehtonen S, et al. The Impact of VEGF-C-Induced Dural Lymphatic Vessel Growth on Ischemic Stroke Pathology. Transl Stroke Res. 2024: 1-19.

[115]

Chong DD, Maatouk CM, Markle J, Shaia JK, Singh RP, Talcott KE. Cardiovascular risk in anti-VEGF treatment of neovascular age-related macular degeneration. Can J Ophthalmol. 2024:S0008-4182(24)00153.

[116]

Marushima A, Nieminen M, Kremenetskaia I, Gianni-Barrera R, Woitzik J, von Degenfeld G, et al. Balanced single-vector co-delivery of VEGF/PDGF-BB improves functional collateralization in chronic cerebral ischemia. J Cereb Blood Flow Metab. 2020; 40: 404-19.

[117]

Anttila V, Saraste A, Knuuti J, Hedman M, Jaakkola P, Laugwitz KL, et al. Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting. Mol Ther. 2023; 31: 866-74.

[118]

Moon S, Chang MS, Koh SH, Choi YK. Repair Mechanisms of the Neurovascular Unit after Ischemic Stroke with a Focus on VEGF. Int J Mol Sci. 2021; 22: 8543.

[119]

Ludwik KA, Hellwig L, Fisch T, Contzen J, Schaar C, Mergenthaler P, et al. Generation of two human induced pluripotent stem cell lines with BAX and BAK1 double knock-out using CRISPR/Cas9. Stem Cell Res. 2024; 76: 103377.

[120]

De Meyer J, Pryck JD, Hachimi-Idrissi S. Stem Cell Therapy for Ischemic Stroke: From Bench to Bedside. Int J Crit Care Emerg Med. 2018; 4: 58.

[121]

Radenovic L. Cerebral ischemia biomarkers: Their roles in early diagnosis and prognosis with potential clinical applications. Brain Heart. 2024; 2: 2750.

[122]

Qin C, Yang S, Chu YH, Zhang H, Pang XW, Chen L, et al. Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2022; 7: 215.

[123]

Croatti A, Longoni M, Montagna S. Applying Telemedicine for Stroke Remote Diagnosis: the TeleStroke System. Procedia Comput Sci. 2022; 198: 164-70.

[124]

Naqvi IA, Cheung YK, Strobino K, Li H, Tom SE, Husaini Z, et al. TASC (Telehealth After Stroke Care): a study protocol for a randomized controlled feasibility trial of telehealth-enabled multidisciplinary stroke care in an underserved urban setting. Pilot Feasibility Stud. 2022; 8: 81.

[125]

Ting WK, Fadul FA, Fecteau S, Ethier C. Neurostimulation for Stroke Rehabilitation. Front Neurosci. 2021; 15: 649459.

[126]

Zhou L, Jin Y, Wu D, Cun Y, Zhang C, Peng Y, et al. Current evidence, clinical applications, and future directions of transcranial magnetic stimulation as a treatment for ischemic stroke. Front Neurosci. 2023; 17: 1177283.

[127]

Cheng J, Fan YQ, Jiang HX, Chen SF, Chen J, Liao XY, et al. Transcranial direct-current stimulation protects against cerebral ischemia-reperfusion injury through regulating Cezanne-dependent signaling. Exp Neurol. 2021; 345: 113818.

[128]

Hong Y, Lyu J, Zhu L, Wang X, Peng M, Chen X, et al. High-frequency repetitive transcranial magnetic stimulation (rTMS) protects against ischemic stroke by inhibiting M1 microglia polarization through let-7b-5p/HMGA2/NF-κB signaling pathway. BMC Neurosci. 2022; 23: 49.

[129]

Chen CM, Wu CT, Yang TH, Liu SH, Yang FY. Preventive Effect of Low Intensity Pulsed Ultrasound against Experimental Cerebral Ischemia/Reperfusion Injury via Apoptosis Reduction and Brain-derived Neurotrophic Factor Induction. Sci Rep. 2018; 8: 5568.

[130]

Bolan F, Louca I, Heal C, Cunningham CJ. The Potential of Biomaterial-Based Approaches as Therapies for Ischemic Stroke: A Systematic Review and Meta-Analysis of Pre-clinical Studies. Front Neurol. 2019; 10: 924.

[131]

Lazăr AI, Aghasoleimani K, Semertsidou A, Vyas J, Roșca AL, Ficai D, et al. Graphene-Related Nanomaterials for Biomedical Applications. Nanomaterials (Basel). 2023; 13: 1092.

[132]

Saadati M, Akhavan O, Fazli H, Nemati S, Baharvand H. Controlled Differentiation of Human Neural Progenitor Cells on Molybdenum Disulfide/Graphene Oxide Heterojunction Scaffolds by Photostimulation. ACS Appl Mater Interfaces. 2023; 15: 3713-30.

[133]

You Y, Xu J, Liu Y, Li H, Xie L, Ma C, et al. Tailored Apoptotic Vesicle Delivery Platform for Inflammatory Regulation and Tissue Repair to Ameliorate Ischemic Stroke. ACS Nano. 2023; 17: 8646-62.

[134]

Poli P, Morone G, Rosati G, Masiero S. Robotic technologies and rehabilitation: new tools for stroke patients’ therapy. Biomed Res Int. 2016; 2016: 153872.

[135]

Otani T, Nishimura N, Yamashita H, Ii S, Yamada S, Watanabe Y, et al. Computational modeling of multiscale collateral blood supply in a whole-brain-scale arterial network. PLoS Comput Biol. 2023; 19: e1011452.

PDF (4377KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉